Martingale Asset Management L P Chinook Therapeutics, Inc. Transaction History

Martingale Asset Management L P

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$18.66 - $38.58 $128,921 - $266,549	-6,909 Reduced 15.17%	38,629 $1.48 Million
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $107 - $134	5 Added 0.01%	45,538 $1.05 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $3,837 - $5,634	206 Added 0.45%	45,533 $1.19 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $71,966 - $96,050	4,110 Added 9.97%	45,327 $892,000
Q2 2022 Aug 11, 2022	BUY	$12.59 - $18.8 $16,367 - $24,440	1,300 Added 3.26%	41,217 $720,000
Q1 2022 May 12, 2022	BUY	$12.02 - $16.69 $143,062 - $198,644	11,902 Added 42.48%	39,917 $653,000
Q4 2021 Feb 11, 2022	BUY	$10.69 - $16.83 $162,488 - $255,815	15,200 Added 118.61%	28,015 $456,000
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $147,372 - $190,430	12,815 New	12,815 $163,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.